Interpace Biosciences
Interpace Diagnostics to Cease PancraGen Testing After Losing CMS Reimbursement
The fate of its pancreatic cancer test had been in limbo for years, but with a newly active LCD from Medicare contractor Novitas, the firm has had to close the book on the assay.
CMS MACs Postpone Implementation of Non-Coverage Decisions for Certain Cancer Genetic Tests
The finalized local coverage determinations were set to go into effect on Feb. 23 but have been pushed back two months.
In Brief This Week: Personalis, Cytek, Interpace, Co-Diagnostics, Thermo Fisher, Bruker, More
News items for the week of Aug. 5, 2024.
In Brief This Week: Interpace Biosciences, 908 Devices, FDA, Quanterix, Co-Diagnostics, More
News items for the week of March 4, 2024.
CMS Contractor Novitas Rescinds Noncoverage Decision for Cancer Genetic Tests
The original decision rescinded coverage for tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Abbott, Clinical Genomics, and the University of Pittsburgh Medical Center.
Jan 13, 2022
Interpace Commences $30M Rights Offering
Nov 11, 2021
Interpace Biosciences Q3 Revenues Rise 15 Percent
Aug 11, 2021
Interpace Biosciences Q2 Revenues More Than Double
May 12, 2021
Interpace Biosciences Q1 Revenues Up 8 Percent
Jan 20, 2021